Assess whether a CMC change is a comparability or a new product

Situation

In a mid-size sponsor after a complete response letter, RWE protocol that may not meet regulator expectations is the evidence after a site-change that invalidates stability claims. Regulatory-affairs lead has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences FDA Response and Labeling close using RWE protocol that may not meet regulator expectations.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.

Hypotheses to test

• Regulatory-affairs lead can defend A CMC change is a comparability from RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims in a Pharma & Life Sciences challenge.
• Regulatory-affairs lead cannot defend A CMC change is a comparability from RWE protocol that may not meet regulator expectations; A new product is what the extract actually supports after a site-change that invalidates stability claims.
• A site-change that invalidates stability claims never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close a CMC change is.
• Two facts in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims conflict for regulatory-affairs lead; hold this FDA Response and Labeling file.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a site-change that invalidates stability claims and write the one fact that would move a CMC change is for regulatory-affairs lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for regulatory-affairs lead in a mid-size sponsor after a complete response letter.